|
US10208023B2
(en)
|
2013-03-01 |
2019-02-19 |
Mark G. DeGiacomo |
Heterocyclic inhibitors of the sodium channel
|
|
US9163042B2
(en)
|
2013-12-13 |
2015-10-20 |
Vertex Pharmaceuticals Incorporated |
Prodrugs of pyridone amides useful as modulators of sodium channels
|
|
EP3110799A4
(en)
*
|
2014-02-27 |
2017-10-11 |
Epirus Biopharmaceuticals, Inc. |
Heterocyclic inhibitors of the sodium channel
|
|
WO2015181797A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
US10407395B2
(en)
*
|
2015-09-11 |
2019-09-10 |
Sumitomo Dainippon Pharma Co., Ltd. |
Benzimidazole compound and medical use thereof
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
KR102714561B1
(ko)
|
2017-05-16 |
2024-10-10 |
버텍스 파마슈티칼스 인코포레이티드 |
나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
|
|
CN110621652A
(zh)
*
|
2017-05-17 |
2019-12-27 |
株式会社德山 |
二氨基苯化合物的制造方法
|
|
TW201920081A
(zh)
|
2017-07-11 |
2019-06-01 |
美商維泰克斯製藥公司 |
作為鈉通道調節劑的羧醯胺
|
|
WO2019138017A1
(en)
*
|
2018-01-15 |
2019-07-18 |
Ucb Biopharma Sprl |
Fused imidazole derivatives as il-17 modulators
|
|
AU2019218387A1
(en)
|
2018-02-12 |
2020-08-27 |
Vertex Pharmaceuticals Incorporated |
A method of treating pain
|
|
WO2020146612A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Esters and carbamates as modulators of sodium channels
|
|
US12441703B2
(en)
|
2019-01-10 |
2025-10-14 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
WO2020176763A1
(en)
|
2019-02-27 |
2020-09-03 |
Vertex Pharmaceuticals Incorporated |
Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
|
|
WO2020219867A1
(en)
|
2019-04-25 |
2020-10-29 |
Vertex Pharmaceuticals Incorporated |
Pyridone amide co-crystal compositions for the treatment of pain
|
|
UY38979A
(es)
|
2019-12-06 |
2021-07-30 |
Vertex Pharma |
Tetrahidrofuranos sustituidos como moduladores de canales de sodio
|
|
AU2021255495A1
(en)
*
|
2020-04-14 |
2022-12-15 |
The Regents Of The University Of California |
Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules
|
|
WO2022108849A1
(en)
*
|
2020-11-17 |
2022-05-27 |
Arisan Therapeutics Inc. |
Heterocyclic compounds as therapeutic agents
|
|
CA3221960A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
|
|
TW202313593A
(zh)
|
2021-06-04 |
2023-04-01 |
美商維泰克斯製藥公司 |
作為鈉通道調節劑之ｎ—（羥基烷基（雜）芳基）四氫呋喃甲醯胺
|
|
EP4347583A1
(en)
|
2021-06-04 |
2024-04-10 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran analogs as modulators of sodium channels
|
|
EP4347584A1
(en)
|
2021-06-04 |
2024-04-10 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
|
|
CN117813302A
(zh)
|
2021-06-04 |
2024-04-02 |
沃泰克斯药物股份有限公司 |
经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
|
|
KR20240031299A
(ko)
|
2021-06-04 |
2024-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
(2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
|
|
CN114249654B
(zh)
*
|
2021-12-30 |
2023-11-14 |
江苏广域化学有限公司 |
烷基苯胺类化合物的制备方法
|
|
WO2023138599A1
(zh)
|
2022-01-18 |
2023-07-27 |
成都康弘药业集团股份有限公司 |
芳香并环类Nav1.8抑制剂及其用途
|
|
CN114288289A
(zh)
*
|
2022-02-17 |
2022-04-08 |
昆山彭济凯丰生物科技有限公司 |
具有镇痛和/或止痒功能的药物组合物及其应用
|
|
IL316462A
(en)
|
2022-04-22 |
2024-12-01 |
Vertex Pharma |
Heteroaryl compounds for the treatment of pain
|
|
CA3256604A1
(en)
|
2022-04-22 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
HETEROARYL COMPOUNDS FOR PAIN RELIEF
|
|
AU2023257313A1
(en)
|
2022-04-22 |
2024-10-31 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
AU2023255558A1
(en)
|
2022-04-22 |
2024-10-31 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
CA3256486A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
|
|
JP2026501116A
(ja)
|
2022-12-06 |
2026-01-14 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
|
|
CN116621789A
(zh)
*
|
2023-05-31 |
2023-08-22 |
上海吉奉生物科技有限公司 |
一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法
|
|
WO2025090511A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
|
|
WO2025090480A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2025090465A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2025090516A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing compounds for treating pain and solid forms thereof
|
|
WO2025122953A1
(en)
|
2023-12-07 |
2025-06-12 |
Vertex Pharmaceuticals Incorporated |
Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
|
|
WO2025160286A1
(en)
|
2024-01-24 |
2025-07-31 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
US20260001877A1
(en)
|
2024-06-28 |
2026-01-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2026013449A2
(en)
|
2024-07-11 |
2026-01-15 |
Sea4Us - Biotecnologia E Recursos Marinhos, Sa |
Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
|